|
Index of reports
> Cases with Hyperkalaemia ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Erbitux (Cetuximab) where reactions include hyperkalaemia. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Erbitux side effects in male
Reported by a physician from Japan on 2012-08-20
Patient: male, weighing 61.0 kg (134.2 pounds)
Reactions: Paronychia, Fatigue, Neuropathy Peripheral, Stomatitis, Diarrhoea, Hyperkalaemia, Hypomagnesaemia, Dermatitis Bullous, Neutrophil Count Decreased
Drug(s) suspected as cause:
Erbitux
Other drugs received by patient: Irinotecan Hydrochloride; Leucovorin Calcium; Fluorouracil
Possible Erbitux side effects in male
Reported by a physician from United States on 2012-04-05
Patient: male, weighing 123.1 kg (270.8 pounds)
Reactions: Dyspnoea, Tumour Lysis Syndrome, Hyperkalaemia, Hypotension, Adrenal Insufficiency
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Carboplatin
Dosage: 900 mg
Erbitux
Dosage: 1514 mg
Taxol
Dosage: 466 mg
Possible Erbitux side effects in female
Reported by a physician from United States on 2012-02-29
Patient: female, weighing 78.0 kg (171.6 pounds)
Reactions: Lymphadenopathy, Metabolic Acidosis, Hyperkalaemia, Sepsis, Pancytopenia, Pulmonary Embolism, Renal Tubular Necrosis, Lung Infiltration, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Erbitux
Dosage: 1248 mg
Taxol
Dosage: 384 mg
Carboplatin
Dosage: 601 mg
Possible Erbitux side effects in male
Reported by a physician from United States on 2012-01-13
Patient: male, weighing 74.8 kg (164.6 pounds)
Reactions: Weight Decreased, Diarrhoea, Hyperkalaemia, Anaemia, Dehydration, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Camptosar
Dosage: 100 mg/m2, on days 1 and 8
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2011-11-28
Erbitux
Dosage: 250 mg/m2, on days 1, 8 and 15
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2010-05-10
RAD 001
Dosage: 5 mg, every other day
Administration route: Oral
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
Possible Erbitux side effects in male
Reported by a physician from United States on 2012-01-05
Patient: male, weighing 74.8 kg (164.6 pounds)
Reactions: Hyperkalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Camptosar
Dosage: 100 mg/m2, on days 1 and 8
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2011-11-28
Erbitux
Dosage: 250 mg/m2, on days 1, 8 and 15
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2010-12-10
RAD 001
Dosage: 5 mg, every other day
Administration route: Oral
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
Possible Erbitux side effects in male
Reported by a physician from United States on 2011-12-29
Patient: male, weighing 74.8 kg (164.6 pounds)
Reactions: Hyperkalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Camptosar
Dosage: 100 mg/m2, on days 1 and 8
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2011-11-28
RAD 001
Dosage: 5 mg, every other day
Administration route: Oral
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
Erbitux
Dosage: 250 mg/m2, on days 1, 8 and 15
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2010-12-10
Possible Erbitux side effects in male
Reported by a physician from United States on 2011-12-22
Patient: male, weighing 74.8 kg (164.6 pounds)
Reactions: Hyperkalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Erbitux
Dosage: 250 mg/m2, on days 1, 8 and 15
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2010-12-10
RAD 001
Dosage: 5 mg, every other day
Administration route: Oral
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
Camptosar
Dosage: 100 mg/m2, on days 1 and 8
Indication: Colorectal Cancer Metastatic
Start date: 2010-05-03
End date: 2011-11-28
Possible Erbitux side effects in 71 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-14
Patient: 71 year old male, weighing 84.0 kg (184.8 pounds)
Reactions: White Blood Cell Count Decreased, Fatigue, Diarrhoea, Hyperkalaemia, Anaemia, Dehydration, Blood Creatinine Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Taxol
Indication: non-Small Cell Lung Cancer
Start date: 2005-04-21
Erbitux
Indication: non-Small Cell Lung Cancer
Start date: 2005-04-21
End date: 2005-08-04
Carboplatin
Indication: non-Small Cell Lung Cancer
Start date: 2005-04-21
End date: 2005-07-28
|
